

# Philip D Harvey

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6941992/publications.pdf>

Version: 2024-02-01

483  
papers

28,002  
citations

5896

81  
h-index

8167

148  
g-index

503  
all docs

503  
docs citations

503  
times ranked

16633  
citing authors

#	ARTICLE	IF	CITATIONS
1	Confidence, accuracy judgments and feedback in schizophrenia and bipolar disorder: a time series network analysis. <i>Psychological Medicine</i> , 2023, 53, 4200-4209.	4.5	2
2	Ecological momentary facial emotion recognition in psychotic disorders. <i>Psychological Medicine</i> , 2022, 52, 2531-2539.	4.5	10
3	Understanding the Course and Correlates of Depression in Older People Undergoing Caregiving Stress. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 158-160.	1.2	0
4	The relationship between cognition and functioning in schizophrenia: A semi-systematic review. <i>Schizophrenia Research: Cognition</i> , 2022, 27, 100217.	1.3	32
5	Improvements in Cognitive Performance With Computerized Training in Older People With and Without Cognitive Impairment: Synergistic Effects of Skills-Focused and Cognitive-Focused Strategies. <i>American Journal of Geriatric Psychiatry</i> , 2022, 30, 717-726.	1.2	6
6	Remote digital phenotyping in serious mental illness: Focus on negative symptoms, mood symptoms, and self-awareness. <i>Biomarkers in Neuropsychiatry</i> , 2022, 6, 100047.	1.0	5
7	Complete blood count inflammatory markers in treatment-resistant schizophrenia: Evidence of association between treatment responsiveness and levels of inflammation. <i>Psychiatry Research</i> , 2022, 308, 114382.	3.3	20
8	Efficacy and Safety of Risperidone for the Treatment of Negative Symptoms of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2022, 48, 609-619.	4.3	22
9	A Longitudinal Examination of Real-World Sedentary Behavior in Adults with Schizophrenia-Spectrum Disorders in a Clinical Trial of Combined Oxytocin and Cognitive Behavioral Social Skills Training. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2022, 12, 60.	2.1	2
10	Brief battery of the Social Cognition Psychometric Evaluation study (BB-SCOPE): Development and validation in schizophrenia spectrum disorders. <i>Journal of Psychiatric Research</i> , 2022, 150, 307-316.	3.1	4
11	A genome-wide association study of suicide attempts in the million veterans program identifies evidence of pan-ancestry and ancestry-specific risk loci. <i>Molecular Psychiatry</i> , 2022, 27, 2264-2272.	7.9	35
12	Momentary severity of psychotic symptoms predicts overestimation of competence in domains of everyday activities and work in schizophrenia: An ecological momentary assessment study. <i>Psychiatry Research</i> , 2022, 310, 114487.	3.3	11
13	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. <i>Schizophrenia Research: Cognition</i> , 2022, 29, 100249.	1.3	23
14	Mobile facial affect recognition and real-time social experiences in serious mental illness. <i>Schizophrenia Research: Cognition</i> , 2022, 29, 100253.	1.3	0
15	Heterogeneity of social cognitive performance in autism and schizophrenia. <i>Autism Research</i> , 2022, 15, 1522-1534.	3.8	6
16	Making Sense of the Matrix: A Qualitative Assessment and Commentary on Connecting Psychiatric Symptom Scale Items to the Research Domain Criteria (RDoC).. <i>Innovations in Clinical Neuroscience</i> , 2022, 19, 26-32.	0.1	3
17	Clinical Management of Patients with Schizophrenia Treated with Long-Acting Injectable Antipsychotics and Telepsychiatry Use During COVID-19 Pandemic. <i>CNS Spectrums</i> , 2022, 27, 230-230.	1.2	2
18	The association of momentary sad moods, concurrent productive behaviour, and global functional outcomes: a 30-day ecological momentary assessment study of people with bipolar illness. <i>Cognitive Neuropsychiatry</i> , 2022, 27, 342-355.	1.3	4

#	ARTICLE	IF	CITATIONS
19	Examining the association of life course neurocognitive ability with real-world functioning in schizophrenia-spectrum disorders. <i>Schizophrenia Research: Cognition</i> , 2022, 29, 100254.	1.3	3
20	Digital Therapeutics to Enhance Cognition in Major Depression: How Can We Make the Cognitive Gains Translate Into Functional Improvements?. <i>American Journal of Psychiatry</i> , 2022, 179, 445-447.	7.2	5
21	Revisiting how people with schizophrenia spend their days: Associations of lifetime milestone achievements with daily activities examined with Ecological Momentary Assessment. <i>Psychiatry Research Communications</i> , 2022, 2, 100060.	1.0	1
22	Pathways from performance monitoring to negative symptoms and functional outcomes in psychotic disorders. <i>Psychological Medicine</i> , 2021, 51, 2012-2022.	4.5	13
23	High-intensity Focused Ultrasound for the Treatment of Prostate Cancer: A National Cohort Study Focusing on the Development of Stricture and Fistulae. <i>European Urology Focus</i> , 2021, 7, 340-346.	3.1	13
24	Prior trauma-related experiences predict the development of posttraumatic stress disorder after a new traumatic event. <i>Depression and Anxiety</i> , 2021, 38, 40-47.	4.1	16
25	The Computerized Functional Skills Assessment and Training Program: Sensitivity to Global Cognitive Impairment, Correlations With Cognitive Abilities, and Factor Structure. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 395-404.	1.2	6
26	Real world sedentary behavior and activity levels in patients with schizophrenia and controls: An ecological momentary assessment study. <i>Mental Health and Physical Activity</i> , 2021, 20, 100364.	1.8	23
27	Better functional capacity and cognitive performance in clozapine responders compared to non-responders: A cross-sectional study. <i>Schizophrenia Research</i> , 2021, 229, 134-136.	2.0	2
28	Genome-Wide Association Studies of Schizophrenia and Bipolar Disorder in a Diverse Cohort of US Veterans. <i>Schizophrenia Bulletin</i> , 2021, 47, 517-529.	4.3	48
29	Avolition as the core negative symptom in schizophrenia: relevance to pharmacological treatment development. <i>NPJ Schizophrenia</i> , 2021, 7, 16.	3.6	42
30	COVID-19-related psychological distress and engagement in preventative behaviors among individuals with severe mental illnesses. <i>NPJ Schizophrenia</i> , 2021, 7, 7.	3.6	16
31	Situational context influences the degree of hostile attributions made by individuals with schizophrenia or autism spectrum disorder. <i>British Journal of Clinical Psychology</i> , 2021, 60, 160-176.	3.5	4
32	Self-reported social functioning and social cognition in schizophrenia and bipolar disorder: Using ecological momentary assessment to identify the origin of bias. <i>Schizophrenia Research</i> , 2021, 230, 17-23.	2.0	30
33	Ecological momentary assessment as a measurement tool in depression trials. <i>Journal of Psychiatric Research</i> , 2021, 136, 256-264.	3.1	24
34	Integration of peripheral transcriptomics, genomics, and interactomics following trauma identifies causal genes for symptoms of post-traumatic stress and major depression. <i>Molecular Psychiatry</i> , 2021, 26, 3077-3092.	7.9	15
35	Addressing Patients'™ Unmet Needs to Improve Outcomes in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2021, 82, .	2.2	2
36	Transcriptome-wide association study of post-trauma symptom trajectories identified GRIN3B as a potential biomarker for PTSD development. <i>Neuropsychopharmacology</i> , 2021, 46, 1811-1820.	5.4	15

#	ARTICLE	IF	CITATIONS
37	Effects of Vortioxetine Versus Placebo on Cognition and Functional Capacity in Adults With Posttraumatic Stress Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, Publish Ahead of Print, 501-503.	1.4	3
38	Evidence for avolition in bipolar disorder? A 30-day ecological momentary assessment comparison of daily activities in bipolar disorder and schizophrenia. <i>Psychiatry Research</i> , 2021, 300, 113924.	3.3	20
39	Cooperative studies Program (CSP) #572: A study of serious mental illness in veterans as a pathway to personalized medicine in schizophrenia and bipolar illness. <i>Personalized Medicine in Psychiatry</i> , 2021, 27-28, 100078.	0.1	0
40	Development of novel measures for Alzheimer's disease prevention trials (NoMAD). <i>Contemporary Clinical Trials</i> , 2021, 106, 106425.	1.8	4
41	Ecological momentary assessment of interpersonal theory of suicide constructs in people experiencing psychotic symptoms. <i>Journal of Psychiatric Research</i> , 2021, 140, 496-503.	3.1	11
42	Using a Meta-cognitive Wisconsin Card Sorting Test to measure introspective accuracy and biases in schizophrenia and bipolar disorder. <i>Journal of Psychiatric Research</i> , 2021, 140, 436-442.	3.1	18
43	Cognitive Endophenotypes: Powerful Tools for Modern Neuropsychiatric Genomics Research. <i>Biological Psychiatry</i> , 2021, 90, 354-355.	1.3	0
44	Computational methods for integrative evaluation of confidence, accuracy, and reaction time in facial affect recognition in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2021, 25, 100196.	1.3	8
45	Autistic symptoms in people with schizophrenia: Neurocognitive, socio-cognitive, clinical and real-world functional characteristics of individuals without autistic features. <i>Schizophrenia Research</i> , 2021, 236, 12-18.	2.0	4
46	Performance-based assessment of social skills in a large sample of participants with schizophrenia, bipolar disorder and healthy controls: Correlates of social competence and social appropriateness. <i>Schizophrenia Research</i> , 2021, 236, 80-86.	2.0	8
47	A cross-diagnostic study of adherence to ecological momentary assessment: Comparisons across study length and daily survey frequency find that early adherence is a potent predictor of study-long adherence. <i>Personalized Medicine in Psychiatry</i> , 2021, 29-30, 100085.	0.1	8
48	Social cognition, neurocognition, symptomatology, functional competences and outcomes in people with schizophrenia – A network analysis perspective. <i>Journal of Psychiatric Research</i> , 2021, 144, 8-13.	3.1	17
49	Daily Ecological Momentary Assessments of happy and sad moods in people with schizophrenia and bipolar disorders: What do participants who are never sad think about their activities and abilities?. <i>Schizophrenia Research: Cognition</i> , 2021, 26, 100202.	1.3	16
50	The clinical characterization of the patient with primary psychosis aimed at personalization of management. <i>World Psychiatry</i> , 2021, 20, 4-33.	10.4	153
51	Lifetime employment in schizophrenia: correlates of developing long term unemployment after being employed before. <i>Cognitive Neuropsychiatry</i> , 2021, 26, 95-106.	1.3	4
52	Remote Ecological Momentary Testing of Learning and Memory in Adults With Serious Mental Illness. <i>Schizophrenia Bulletin</i> , 2021, 47, 740-750.	4.3	15
53	The relationship between substance use, prior trauma history, and risk of developing post-traumatic stress disorder in the immediate aftermath of civilian trauma. <i>Journal of Psychiatric Research</i> , 2021, 144, 345-352.	3.1	2
54	Capturing Clinical Symptoms with Ecological Momentary Assessment: Convergence of Momentary Reports of Psychotic and Mood Symptoms with Diagnoses and Standard Clinical Assessments. <i>Innovations in Clinical Neuroscience</i> , 2021, 18, 24-30.	0.1	5

#	ARTICLE	IF	CITATIONS
55	Validity of remote administration of the MATRICS Consensus Cognitive Battery for individuals with severe mental illness. <i>Schizophrenia Research: Cognition</i> , 2021, 27, 100226.	1.3	2
56	Schizophrenia in Older Adults. , 2021, , 4374-4382.		0
57	Neurocognition and social cognition in patients with schizophrenia spectrum disorders with and without a history of violence: results of a multinational European study. <i>Translational Psychiatry</i> , 2021, 11, 620.	4.8	12
58	Childhood Trauma Associations With the Interpersonal Psychological Theory of Suicide and Social Cognitive Biases in Psychotic Disorders. <i>Journal of Nervous and Mental Disease</i> , 2021, Publish Ahead of Print, .	1.0	5
59	Confidence, performance, and accuracy of self-assessment of social cognition: A comparison of schizophrenia patients and healthy controls. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100133.	1.3	32
60	Training engagement, baseline cognitive functioning, and cognitive gains with computerized cognitive training: A cross-diagnostic study. <i>Schizophrenia Research: Cognition</i> , 2020, 19, 100150.	1.3	20
61	Using self-reported vocational functioning measures to identify employed patients with impaired functional capacity in major depressive disorder. <i>Journal of Affective Disorders</i> , 2020, 260, 550-556.	4.1	2
62	Comprehensive comparison of social cognitive performance in autism spectrum disorder and schizophrenia. <i>Psychological Medicine</i> , 2020, 50, 2557-2565.	4.5	64
63	Effects of Risperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expression. <i>Schizophrenia Research</i> , 2020, 215, 352-356.	2.0	19
64	Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis. <i>Current Medical Research and Opinion</i> , 2020, 36, 117-124.	1.9	7
65	Neurocognition and social cognition training as treatments for violence and aggression in people with severe mental illness. <i>CNS Spectrums</i> , 2020, 25, 145-153.	1.2	14
66	Pharmacological treatment of violence in schizophrenia. <i>CNS Spectrums</i> , 2020, 25, 207-215.	1.2	13
67	Depression predicts self assessment of social function in both patients with schizophrenia and healthy people. <i>Psychiatry Research</i> , 2020, 284, 112681.	3.3	22
68	Cognition, Social Cognition, and Functional Capacity in Early-Onset Schizophrenia. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2020, 29, 171-182.	1.9	33
69	Correlates of loneliness among persons with psychotic disorders. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 549-559.	3.1	31
70	Genome-wide association study of cognitive performance in U.S. veterans with schizophrenia or bipolar disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2020, 183, 181-194.	1.7	17
71	Blonanserin vs risperidone in Japanese patients with schizophrenia: A post hoc analysis of a phase 3, 8-week, multicenter, double-blind, randomized controlled study. <i>Neuropsychopharmacology Reports</i> , 2020, 40, 63-72.	2.3	12
72	Autistic symptoms predict social cognitive performance in patients with schizophrenia.. <i>Schizophrenia Research</i> , 2020, 215, 113-119.	2.0	22

#	ARTICLE	IF	CITATIONS
73	Older versus middle-aged adults with schizophrenia: Executive functioning and community outcomes. <i>Schizophrenia Research</i> , 2020, 216, 547-549.	2.0	5
74	M120. IMPAIRED CLINICAL INSIGHT AS A PREDICTOR OF RELAPSE IN SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2020, 46, S180-S181.	4.3	0
75	S221. THE EFFICACY OF LUMATEPERONE 42 MG IN THE TREATMENT OF SCHIZOPHRENIA SYMPTOMS ASSOCIATED WITH SOCIAL FUNCTIONING: POST HOC ANALYSIS OF AN ACUTE PLACEBO- AND ACTIVE-CONTROLLED TRIAL. <i>Schizophrenia Bulletin</i> , 2020, 46, S123-S123.	4.3	0
76	S223. DETERMINANTS OF SUSTAINED UNEMPLOYMENT IN FORMERLY EMPLOYED SCHIZOPHRENIA PATIENTS. <i>Schizophrenia Bulletin</i> , 2020, 46, S123-S124.	4.3	0
77	Association of C-reactive protein and metabolic risk with cognitive effects of lurasidone in patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2020, 102, 152195.	3.1	5
78	S173. GENOME-WIDE ASSOCIATION STUDIES OF SCHIZOPHRENIA AND BIPOLAR DISORDER IN A DIVERSE COHORT OF US VETERANS. <i>Schizophrenia Bulletin</i> , 2020, 46, S103-S103.	4.3	1
79	Depression, hostility, attributional biases, and paranoia in schizophrenia and healthy controls: intercorrelations and associations with self-assessment of social functioning. <i>Psychiatry Research</i> , 2020, 293, 113388.	3.3	1
80	Factor structure of cognitive performance and functional capacity in schizophrenia: Evidence for differences across functional capacity measures. <i>Schizophrenia Research</i> , 2020, 223, 297-304.	2.0	9
81	Requisite Skills and the Meaningful Measurement of Cognition. <i>JAMA Psychiatry</i> , 2020, 77, 1103.	11.0	0
82	Overconfidence in social cognitive decision making: Correlations with social cognitive and neurocognitive performance in participants with schizophrenia and healthy individuals. <i>Schizophrenia Research</i> , 2020, 224, 51-57.	2.0	18
83	Neighborhood socioeconomic status and racial disparities in schizophrenia: An exploration of domains of functioning. <i>Schizophrenia Research</i> , 2020, 224, 95-101.	2.0	9
84	Emotional determinants of life-space through GPS and ecological momentary assessment in schizophrenia: What gets people out of the house?. <i>Schizophrenia Research</i> , 2020, 224, 67-73.	2.0	26
85	Major Neuropsychological Impairments in Schizophrenia Patients: Clinical Implications. <i>Current Psychiatry Reports</i> , 2020, 22, 59.	4.5	6
86	O1.6. AFFECTIVE DETERMINANTS OF LIFE-SPACE THROUGH GPS AND ECOLOGICAL MOMENTARY ASSESSMENT IN SCHIZOPHRENIA: WHAT GETS PEOPLE OUT OF THE HOUSE?. <i>Schizophrenia Bulletin</i> , 2020, 46, S3-S3.	4.3	0
87	Measuring mentalizing: A comparison of scoring methods for the hinting task. <i>International Journal of Methods in Psychiatric Research</i> , 2020, 29, e1827.	2.1	9
88	An Array of Studies Addressing Cognition and Cognitively Defined Neuropsychiatric Conditions: Many More Connections Than You Might Think. <i>American Journal of Psychiatry</i> , 2020, 177, 491-496.	7.2	2
89	Emerging 5-HT receptor antagonists for the treatment of Schizophrenia. <i>Expert Opinion on Emerging Drugs</i> , 2020, 25, 189-200.	2.4	15
90	A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills. <i>Journal of Visualized Experiments</i> , 2020, . .	0.3	3

#	ARTICLE	IF	CITATIONS
91	Autistic Symptoms and Social Cognition Predict Real-World Outcomes in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 524.	2.6	23
92	Psychometric properties of the Observable Social Cognition Rating Scale (OSCARS): Self-report and informant-rated social cognitive abilities in schizophrenia. <i>Psychiatry Research</i> , 2020, 286, 112891.	3.3	13
93	Cyberbullying and Its Relationship to Current Symptoms and History of Early Life Trauma. <i>Journal of Clinical Psychiatry</i> , 2020, 81, .	2.2	11
94	Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial. <i>Clinical Drug Investigation</i> , 2020, 40, 377-385.	2.2	14
95	Suicidal ideation, behavior, and mortality in male and female US veterans with severe mental illness. <i>Journal of Affective Disorders</i> , 2020, 267, 144-152.	4.1	13
96	The Impact of Intellectual Disability and Autism Spectrum Disorder on Restraint and Seclusion in Pre-Adolescent Psychiatric Inpatients. <i>Journal of Mental Health Research in Intellectual Disabilities</i> , 2020, 13, 86-109.	2.0	7
97	A Longitudinal Investigation of the Effects of the COVID-19 Pandemic on the Mental Health of Individuals with Pre-existing Severe Mental Illnesses. <i>Psychiatry Research</i> , 2020, 294, 113493.	3.3	99
98	Evaluation of a Novel Technology-Based Program Designed to Assess and Train Everyday Skills in Older Adults. <i>Innovation in Aging</i> , 2020, 4, igaa052.	0.1	17
99	DEVELOPMENT OF AN UPSA SHORT FORM FOR USE IN LONGITUDINAL STUDIES IN THE EARLY ALZHEIMERâ€™S DISEASE SPECTRUM. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2020, 7, 1-5.	2.7	8
100	Assessing the Real-Time Mental Health Challenges of COVID-19 in Individuals With Serious Mental Illnesses: Protocol for a Quantitative Study. <i>JMIR Research Protocols</i> , 2020, 9, e19203.	1.0	15
101	Schizophrenia in Older Adults. , 2020, , .		0
102	Cardiovascular, endothelial function, and immune markers in response to treatment with a polysaccharide in HIV adults in a randomized, double-blind placebo-controlled trial. <i>Journal of Clinical and Translational Research</i> , 2020, 5, 140-147.	0.3	2
103	Helping older adults overcome the challenges of technology. , 2020, 19, .		3
104	Paranoia and interpersonal functioning across the continuum from healthy to pathological â€œ Network analysis. <i>British Journal of Clinical Psychology</i> , 2019, 58, 19-34.	3.5	29
105	Temporal Stability of Cognitive Functioning and Functional Capacity in Women with Posttraumatic Stress Disorder. <i>Archives of Clinical Neuropsychology</i> , 2019, 34, 539-547.	0.5	4
106	What Do People With Schizophrenia Do All Day? Ecological Momentary Assessment of Real-World Functioning in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 46, 242-251.	4.3	64
107	Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment. <i>Journal of Experimental Psychopathology</i> , 2019, 10, 204380871986569.	0.8	58
108	S123. PREDICTORS OF SOCIAL FUNCTIONING IN PATIENTS WITH HIGHER AND LOWER LEVELS OF REDUCED EMOTIONAL EXPERIENCE: SOCIAL COGNITION, SOCIAL COMPETENCE, AND SYMPTOM SEVERITY. <i>Schizophrenia Bulletin</i> , 2019, 45, S353-S353.	4.3	0

#	ARTICLE	IF	CITATIONS
109	GPS mobility as a digital biomarker of negative symptoms in schizophrenia: a case control study. <i>Npj Digital Medicine</i> , 2019, 2, 108.	10.9	74
110	F53. IMPROVED FUNCTIONAL CAPACITY AND COGNITIVE PERFORMANCE IN CLOZAPINE RESPONDERS COMPARED TO NON-RESPONDERS. <i>Schizophrenia Bulletin</i> , 2019, 45, S275-S276.	4.3	1
111	S11. GENETIC INFLUENCES ON LACK OF INSIGHT: THE ROLE OF CATECHOL-O-METHYLTRANSFERASE (COMT) GENE POLYMORPHISMS. <i>Schizophrenia Bulletin</i> , 2019, 45, S310-S310.	4.3	0
112	S43. SADDER BUT WISER: DEPRESSION OUTWEIGHS SEX AND SCHIZOPHRENIA IN SELF ASSESSMENT OF INTERPERSONAL FUNCTIONING. <i>Schizophrenia Bulletin</i> , 2019, 45, S322-S323.	4.3	0
113	S93. GENOMICS OF SUICIDAL IDEATION AND BEHAVIOR IN VETERANS WITH SCHIZOPHRENIA AND BIPOLAR ILLNESS. <i>Schizophrenia Bulletin</i> , 2019, 45, S342-S342.	4.3	0
114	O5.7. VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT IN PATIENTS WITH SCHIZOPHRENIA: CORRELATES OF PERFORMANCE OF SOLITARY AND SOCIALLY RELEVANT TASKS. <i>Schizophrenia Bulletin</i> , 2019, 45, S175-S175.	4.3	1
115	O6.6. REAL WORLD SEDENTARY BEHAVIOR AND ACTIVITY LEVELS IN PATIENTS WITH SCHIZOPHRENIA AND CONTROLS DERIVED FROM ECOLOGICAL MOMENTARY ASSESSMENT. <i>Schizophrenia Bulletin</i> , 2019, 45, S178-S178.	4.3	3
116	Depression and reduced emotional experience in schizophrenia: Correlations with self-reported and informant-rated everyday social functioning. <i>Journal of Experimental Psychopathology</i> , 2019, 10, 204380871982931.	0.8	6
117	O4.4. CONFIDENCE, PERFORMANCE, AND ACCURACY OF SELF-ASSESSMENT OF SOCIAL COGNITION: A COMPARISON OF SCHIZOPHRENIA PATIENTS AND HEALTHY CONTROLS. <i>Schizophrenia Bulletin</i> , 2019, 45, S170-S170.	4.3	0
118	Cognition, social cognition, and Self-assessment in schizophrenia: prediction of different elements of everyday functional outcomes. <i>CNS Spectrums</i> , 2019, 24, 88-93.	1.2	45
119	Smoking Cannabis and Acquired Impairments in Cognition: Starting Early Seems Like a Really Bad Idea. <i>American Journal of Psychiatry</i> , 2019, 176, 90-91.	7.2	4
120	The International Consortium Investigating Neurocognition in Bipolar Disorder ( ICONIC â€•BD ). <i>Bipolar Disorders</i> , 2019, 21, 6-10.	1.9	12
121	Guanfacine Augmentation of a Combined Intervention of Computerized Cognitive Remediation Therapy and Social Skills Training for Schizotypal Personality Disorder. <i>American Journal of Psychiatry</i> , 2019, 176, 307-314.	7.2	24
122	Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. <i>Psychiatry Research</i> , 2019, 277, 58-63.	3.3	10
123	Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). <i>Schizophrenia Research</i> , 2019, 210, 30-38.	2.0	7
124	Functional deficits in attenuated psychosis syndrome and related conditions: Current and future treatment options. <i>Schizophrenia Research: Cognition</i> , 2019, 17, 100152.	1.3	6
125	Cognition and disability in schizophrenia: cognitionâ€™related skills deficits and decisionâ€™making challenges add to morbidity. <i>World Psychiatry</i> , 2019, 18, 165-167.	10.4	27
126	Autism symptoms, depression, and active social avoidance in schizophrenia: Association with self-reports and informant assessments of everyday functioning. <i>Journal of Psychiatric Research</i> , 2019, 115, 36-42.	3.1	50



#	ARTICLE	IF	CITATIONS
127	Assessment of social cognition. , 2019, , 219-247.		0
128	Shape of Training Review: an impact assessment for UK gastroenterology trainees. Frontline Gastroenterology, 2019, 10, 356-363.	1.8	32
129	Blonanserin versus haloperidol in Japanese patients with schizophrenia: A phase 3, 8-week, double-blind, multicenter, randomized controlled study. Neuropsychopharmacology Reports, 2019, 39, 173-182.	2.3	15
130	Glutamate modulators for treatment of schizophrenia. Personalized Medicine in Psychiatry, 2019, 15-16, 1-12.	0.1	8
131	Predictors of social functioning in patients with higher and lower levels of reduced emotional experience: Social cognition, social competence, and symptom severity. Schizophrenia Research, 2019, 206, 271-276.	2.0	21
132	Expert Consensus on Screening and Assessment of Cognition in Psychiatry. CNS Spectrums, 2019, 24, 154-162.	1.2	18
133	Impaired introspective accuracy in schizophrenia: an independent predictor of functional outcomes. Cognitive Neuropsychiatry, 2019, 24, 28-39.	1.3	38
134	Domains of cognition and their assessment. Dialogues in Clinical Neuroscience, 2019, 21, 227-237.	3.7	251
135	Schizophrenia in Older Adults. , 2019, , 1-9.		0
136	Associations of independent living and labor force participation with impairment indicators in schizophrenia and bipolar disorder at 20-year follow-up. Schizophrenia Research, 2018, 197, 150-155.	2.0	44
137	Interpersonal beliefs related to suicide and facial emotion processing in psychotic disorders. Journal of Psychiatric Research, 2018, 100, 107-112.	3.1	25
138	Self-assessment of social cognitive ability in schizophrenia: Association with social cognitive test performance, informant assessments of social cognitive ability, and everyday outcomes. Schizophrenia Research, 2018, 199, 75-82.	2.0	65
139	No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. European Heart Journal, 2018, 39, 374-381.	2.2	57
140	Social Skills Training for Negative Symptoms of Schizophrenia. Schizophrenia Bulletin, 2018, 44, 472-474.	4.3	24
141	Suicidal ideation and behavior in US veterans with schizophrenia or bipolar disorder. Journal of Psychiatric Research, 2018, 102, 216-222.	3.1	26
142	Social Cognition Psychometric Evaluation: Results of the Final Validation Study. Schizophrenia Bulletin, 2018, 44, 737-748.	4.3	187
143	Placebo Effects Across Self-Report, Clinician Rating, and Objective Performance Tasks Among Women With Post-Traumatic Stress Disorder. Journal of Clinical Psychopharmacology, 2018, 38, 200-206.	1.4	13
144	Cognitive and functional deficits in people with schizophrenia: Evidence for accelerated or exaggerated aging?. Schizophrenia Research, 2018, 196, 14-21.	2.0	61

#	ARTICLE	IF	CITATIONS
145	Associations of suicidality with cognitive ability and cognitive insight in outpatients with Schizophrenia. Schizophrenia Research, 2018, 192, 340-344.	2.0	33
146	What Is So Different About Psychotic Patients Who Have Extremely Long Institutional Stays?. American Journal of Geriatric Psychiatry, 2018, 26, 198-199.	1.2	0
147	A novel cognitive assessment paradigm to detect Pre-mild cognitive impairment ( PreMCI ) and the relationship to biological markers of Alzheimer's disease. Journal of Psychiatric Research, 2018, 96, 33-38.	3.1	26
148	Tardive dyskinesia: motor system impairments, cognition and everyday functioning. CNS Spectrums, 2018, 23, 370-377.	1.2	28
149	Thought, language, and communication deficits and association with everyday functional outcomes among community-dwelling middle-aged and older adults with schizophrenia. Schizophrenia Research, 2018, 196, 29-34.	2.0	20
150	F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE. Schizophrenia Bulletin, 2018, 44, S242-S243.	4.3	0
151	F250. DEPRESSION IN SCHIZOPHRENIA: CORRELATIONS WITH OBJECTIVE AND SUBJECTIVE QUALITY OF LIFE OUTCOMES. Schizophrenia Bulletin, 2018, 44, S320-S320.	4.3	0
152	S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY. Schizophrenia Bulletin, 2018, 44, S353-S353.	4.3	1
153	24.4 COGNITION AND COMMUNICATION AS DETERMINANTS OF ADAPTIVE DEFICITS IN LATE LIFE SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S40-S40.	4.3	0
154	Cigarette Smoking, Cognitive Performance, and Severe Mental Illness: Quitting Smoking Really Does Seem to Matter. American Journal of Psychiatry, 2018, 175, 1054-1055.	7.2	4
155	Social cognition and short-term prediction of suicidal ideation in schizophrenia. Psychiatry Research, 2018, 270, 13-19.	3.3	23
156	Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms. Journal of Clinical Psychiatry, 2018, 79, .	2.2	24
157	Cognitive and functional deficits in bipolar disorder and schizophrenia as a function of the presence and history of psychosis. Bipolar Disorders, 2018, 20, 604-613.	1.9	31
158	Social cognitive impairments in individuals with schizophrenia vary in severity. Journal of Psychiatric Research, 2018, 104, 65-71.	3.1	33
159	Neural correlates of social cognitive introspective accuracy in schizophrenia. Schizophrenia Research, 2018, 202, 166-172.	2.0	30
160	The Course of Cognition and Functioning in Patients at Ultrahigh Risk of Developing Psychosis. JAMA Psychiatry, 2018, 75, 882.	11.0	3
161	Controversies in Computerized Cognitive Training. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2018, 3, 907-915.	1.5	63
162	Which levels of cognitive impairments and negative symptoms are related to functional deficits in schizophrenia?. Journal of Psychiatric Research, 2018, 104, 124-129.	3.1	63

#	ARTICLE	IF	CITATIONS
163	T111. PANSS NEGATIVE SYMPTOM DIMENSIONS ACROSS GEOGRAPHICAL REGIONS: IMPLICATIONS FOR SOCIAL, LINGUISTIC AND CULTURAL CONSISTENCY. <i>Schizophrenia Bulletin</i> , 2018, 44, S159-S159.	4.3	0
164	Evaluating social skill in individuals with schizophrenia with the brief impression questionnaire (BIQ). <i>Psychiatry Research</i> , 2018, 269, 38-44.	3.3	2
165	Associations of Age and Gender with Negative Symptom Factors and Functioning Among Middle-Aged and Older Adults with Schizophrenia. <i>American Journal of Geriatric Psychiatry</i> , 2018, 26, 1215-1219.	1.2	16
166	T235. SELF ASSESSMENT OF SOCIAL COGNITIVE ABILITY IN SCHIZOPHRENIA: ASSOCIATION WITH SOCIAL COGNITIVE TEST PERFORMANCE, INFORMANT ASSESSMENTS OF SOCIAL COGNITIVE ABILITY, AND EVERYDAY OUTCOMES. <i>Schizophrenia Bulletin</i> , 2018, 44, S208-S208.	4.3	0
167	Social Cognition and Neurocognition in Schizophrenia and Healthy Controls: Intercorrelations of Performance and Effects of Manipulations Aimed at Increasing Task Difficulty. <i>Frontiers in Psychiatry</i> , 2018, 9, 356.	2.6	31
168	Combining training leads to better results: Implications for clinical delivery of computerized cognitive and social cognitive training. <i>Schizophrenia Research</i> , 2018, 202, 48-49.	2.0	1
169	Correlates of risk factors for reduced life expectancy in schizophrenia: Is it possible to develop a predictor profile?. <i>Schizophrenia Research</i> , 2018, 201, 388-392.	2.0	15
170	The bias toward intentionality in schizophrenia: Automaticity, context, and relationships to symptoms and functioning.. <i>Journal of Abnormal Psychology</i> , 2018, 127, 503-512.	1.9	17
171	Validation of the tablet-administered Brief Assessment of Cognition (BAC App). <i>Schizophrenia Research</i> , 2017, 181, 100-106.	2.0	62
172	Assessing functional performance using computer-based simulations of everyday activities. <i>Schizophrenia Research</i> , 2017, 183, 130-136.	2.0	22
173	Examining the reliability and validity of the Clinical Assessment Interview for Negative Symptoms within the Management of Schizophrenia in Clinical Practice (MOSAIC) multisite national study. <i>Schizophrenia Research</i> , 2017, 185, 137-143.	2.0	31
174	Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder. <i>Journal of Affective Disorders</i> , 2017, 213, 105-111.	4.1	15
175	Exploratory analysis of normative performance on the UCSD Performance-Based Skills Assessment-Brief. <i>Psychiatry Research</i> , 2017, 256, 150-155.	3.3	16
176	Placebo Response and Practice Effects in Schizophrenia Cognition Trials. <i>JAMA Psychiatry</i> , 2017, 74, 807.	11.0	34
177	Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments. <i>International Clinical Psychopharmacology</i> , 2017, 32, 72-79.	1.7	10
178	Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. <i>Bipolar Disorders</i> , 2017, 19, 336-343.	1.9	52
179	A Novel Method for Direct Assessment of Everyday Competence Among Older Adults. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1229-1238.	2.6	27
180	Social cognition psychometric evaluation (SCOPE) in people with early psychosis: A preliminary study. <i>Schizophrenia Research</i> , 2017, 190, 136-143.	2.0	53

#	ARTICLE	IF	CITATIONS
181	Impact of genotyping errors on statistical power of association tests in genomic analyses: A case study. <i>Genetic Epidemiology</i> , 2017, 41, 152-162.	1.3	12
182	The Effect of Age, Race, and Sex on Social Cognitive Performance in Individuals With Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 2017, 205, 346-352.	1.0	30
183	M36. Social Cognition Psychometric Evaluation (SCOPE): Results: Of the Final Validation Study. <i>Schizophrenia Bulletin</i> , 2017, 43, S224-S225.	4.3	6
184	M33. Recognition of Fearful Faces Depends on Depressive Symptoms in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, S223-S223.	4.3	0
185	Inflammation in Schizophrenia: What It Means and How to Treat It. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 62-63.	1.2	2
186	Measuring and Facilitating Client Engagement with Financial Incentives: Implications for Improving Clinical Outcomes in a Mental Health Setting. <i>Community Mental Health Journal</i> , 2017, 53, 501-509.	2.0	4
187	Self-assessment of social cognitive ability in individuals with schizophrenia: Appraising task difficulty and allocation of effort. <i>Schizophrenia Research</i> , 2017, 179, 85-90.	2.0	24
188	Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017, 8, 177.	2.6	25
189	61.4 Neural Correlates of Introspective Accuracy in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2017, 43, S36-S37.	4.3	0
190	M25. Development and Validation of the Brief Assessment of Validation in Schizophrenia (BAC-App). <i>Schizophrenia Bulletin</i> , 2017, 43, S220-S220.	4.3	2
191	Schizophrenia and Related Conditions in Late Life $\hat{a}$ †. , 2017, , .		0
192	61.1 Introspective Accuracy as a Predictor of Real-World Outcomes. <i>Schizophrenia Bulletin</i> , 2017, 43, S35-S36.	4.3	6
193	Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder. <i>Journal of Psychiatric Research</i> , 2017, 94, 180-185.	3.1	24
194	Performance-based and Observational Assessments in Clinical Trials Across the Alzheimer's Disease Spectrum. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 30-39.	0.1	6
195	Using the Positive and Negative Syndrome Scale (PANSS) to Define Different Domains of Negative Symptoms: Prediction of Everyday Functioning by Impairments in Emotional Expression and Emotional Experience. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 18-22.	0.1	39
196	Insight and Treatment Outcomes in Schizophrenia: Analysis of a Long-term, Double-blind Study Comparing Lurasidone and Quetiapine XR. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 23-29.	0.1	3
197	Negative Symptom Dimensions of the Positive and Negative Syndrome Scale Across Geographical Regions: Implications for Social, Linguistic, and Cultural Consistency. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 30-40.	0.1	61
198	Randomized Prospective Double-Blind Studies to Evaluate the Cognitive Effects of Inositol-Stabilized Arginine Silicate in Healthy Physically Active Adults. <i>Nutrients</i> , 2016, 8, 736.	4.1	13

#	ARTICLE	IF	CITATIONS
199	Lurasidone Effects on Cognition and Functional Capacity in Schizophrenia. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2016, 7, 11-19.	0.3	0
200	Revisiting the validity of measures of social cognitive bias in schizophrenia: Additional results from the Social Cognition Psychometric Evaluation (SCOPE) study. <i>British Journal of Clinical Psychology</i> , 2016, 55, 441-454.	3.5	39
201	Treatment resistant schizophrenia: Course of brain structure and function. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2016, 70, 111-116.	4.8	23
202	Paranoid individuals with schizophrenia show greater social cognitive bias and worse social functioning than non-paranoid individuals with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2016, 3, 33-38.	1.3	59
203	Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. <i>Brain, Behavior, and Immunity</i> , 2016, 56, 281-288.	4.1	102
204	Functional Capacity Assessed by the Map Task in Individuals at Clinical High-Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2016, 42, 1234-1242.	4.3	17
205	Does neuropsychological performance impact on real-life functional achievements in obsessive-compulsive disorder? A preliminary study. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 224-231.	2.4	7
206	Validation of a Computerized test of Functional Capacity. <i>Schizophrenia Research</i> , 2016, 175, 90-96.	2.0	53
207	Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2016, 5, 7-12.	1.3	6
208	Depression in Schizophrenia: Associations With Cognition, Functional Capacity, Everyday Functioning, and Self-Assessment. <i>Schizophrenia Bulletin</i> , 2016, 43, sbw103.	4.3	43
209	Social cognition in schizophrenia: Factor structure of emotion processing and theory of mind. <i>Psychiatry Research</i> , 2016, 242, 150-156.	3.3	41
210	Social Cognition Psychometric Evaluation: Results of the Initial Psychometric Study. <i>Schizophrenia Bulletin</i> , 2016, 42, 494-504.	4.3	219
211	A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness. <i>Psychoneuroendocrinology</i> , 2016, 64, 22-30.	2.7	42
212	Neurocognitive insight and objective cognitive functioning in schizophrenia. <i>Schizophrenia Research</i> , 2016, 171, 131-136.	2.0	32
213	Factor structure of cognition and functional capacity in two studies of schizophrenia and bipolar disorder: Implications for genomic studies.. <i>Neuropsychology</i> , 2016, 30, 28-39.	1.3	33
214	A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processingâ€œFocused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. <i>Journal of Clinical Psychiatry</i> , 2016, 77, 799-806.	2.2	22
215	Designing a Web-Based Application to Train Aging Adults to Successfully Use Technologies Important to Independent Living. <i>Lecture Notes in Computer Science</i> , 2016, , 289-299.	1.3	0
216	Dr Kantrowitz and Colleagues Reply. <i>Journal of Clinical Psychiatry</i> , 2016, 77, e1353-e1353.	2.2	0

#	ARTICLE	IF	CITATIONS
217	Factors predicting work outcome in Japanese patients with schizophrenia: role of multiple functioning levels. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 105-112.	1.3	15
218	Self-assessment in schizophrenia: Accuracy of evaluation of cognition and everyday functioning. <i>Neuropsychology</i> , 2015, 29, 675-682.	1.3	93
219	The Happy Older Latinos are Active (HOLA) health promotion and prevention study: study protocol for a pilot randomized controlled trial. <i>Trials</i> , 2015, 16, 579.	1.6	20
220	The clinical utility of lurasidone in schizophrenia: patient considerations. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 1103.	2.2	7
221	Effects of the D1 Dopamine Receptor Agonist Dihydropyridine (DAR-0100A) on Working Memory in Schizotypal Personality Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 446-453.	5.4	83
222	The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: An analysis of the CATIE Schizophrenia Trial. <i>Schizophrenia Research</i> , 2015, 166, 110-114.	2.0	11
223	Understanding Symbol Coding in Schizophrenia. <i>Biological Psychiatry</i> , 2015, 78, 744-746.	1.3	5
224	Absence of bias in clinician ratings of everyday functioning among African American, Hispanic and Caucasian patients with schizophrenia. <i>Psychiatry Research</i> , 2015, 229, 347-352.	3.3	6
225	Report on ISCTM Consensus Meeting on Clinical Assessment of Response to Treatment of Cognitive Impairment in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 42, sbv111.	4.3	34
226	Factors influencing self-assessment of cognition and functioning in bipolar disorder: a preliminary study. <i>Cognitive Neuropsychiatry</i> , 2015, 20, 361-371.	1.3	27
227	Determinants of different aspects of everyday outcome in schizophrenia: The roles of negative symptoms, cognition, and functional capacity. <i>Schizophrenia Research</i> , 2015, 165, 76-82.	2.0	150
228	Editorial. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 1.	1.3	2
229	Practice effects due to serial cognitive assessment: Implications for preclinical Alzheimer's disease randomized controlled trials. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 103-111.	2.4	191
230	High velocity circuit resistance training improves cognition, psychiatric symptoms and neuromuscular performance in overweight outpatients with severe mental illness. <i>Psychiatry Research</i> , 2015, 229, 295-301.	3.3	47
231	Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia. <i>Journal of Psychiatric Research</i> , 2015, 68, 254-260.	3.1	107
232	Insight and subjective measures of quality of life in chronic schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 127-132.	1.3	47
233	The Management of Schizophrenia in Clinical Practice (MOSAIC) Registry: A focus on patients, caregivers, illness severity, functional status, disease burden and healthcare utilization. <i>Schizophrenia Research</i> , 2015, 166, 69-79.	2.0	20
234	Factors influencing self-assessment of cognition and functioning in schizophrenia: Implications for treatment studies. <i>European Neuropsychopharmacology</i> , 2015, 25, 185-191.	0.7	75

#	ARTICLE	IF	CITATIONS
235	Reliability, validity and treatment sensitivity of the Schizophrenia Cognition Rating Scale. <i>European Neuropsychopharmacology</i> , 2015, 25, 176-184.	0.7	44
236	Methods for Delivering and Evaluating the Efficacy of Cognitive Enhancement. <i>Handbook of Experimental Pharmacology</i> , 2015, 228, 5-25.	1.8	3
237	Cognitive performance, symptom severity, and survival among patients with schizophrenia spectrum disorder: A prospective 15-year study. <i>Schizophrenia Research</i> , 2015, 169, 141-146.	2.0	14
238	Improving the understanding of the link between cognition and functional capacity in schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2015, 169, 121-127.	2.0	13
239	Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study. <i>Schizophrenia Research</i> , 2015, 166, 334-338.	2.0	24
240	Latest Developments in Cognitive Functioning in Mood and Anxiety Disorders. <i>Current Behavioral Neuroscience Reports</i> , 2015, 2, 165-172.	1.3	0
241	Clozapine improves the orienting of attention in schizophrenia. <i>Schizophrenia Research</i> , 2015, 168, 285-291.	2.0	30
242	ASSESSMENT OF AGE-RELATED DIFFERENCES IN FUNCTIONAL CAPACITY USING THE VIRTUAL REALITY FUNCTIONAL CAPACITY ASSESSMENT TOOL (VRFCAT). <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2015, 2, 1-7.	2.7	23
243	Restraint and seclusion as therapeutic interventions: changes across consecutive admissions. <i>Journal of Psychiatric Intensive Care</i> , 2014, 10, 84-92.	0.6	2
244	Physical performance and disability in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 112-121.	1.3	56
245	Utility of the UCSD Performance-based Skills Assessment-Brief Japanese version: discriminative ability and relation to neurocognition. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 137-143.	1.3	22
246	Social competence versus negative symptoms as predictors of real world social functioning in schizophrenia. <i>Schizophrenia Research</i> , 2014, 160, 136-141.	2.0	100
247	The genetics of functional disability in schizophrenia and bipolar illness: Methods and initial results for VA cooperative study #572. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2014, 165, 381-389.	1.7	36
248	Association of obesity and treated hypertension and diabetes with cognitive ability in bipolar disorder and schizophrenia. <i>Bipolar Disorders</i> , 2014, 16, 422-431.	1.9	71
249	Treatment resistance and other complicating factors in the management of schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 13-24.	1.2	7
250	The evolution of illness phases in schizophrenia: A non-parametric item response analysis of the Positive and Negative Syndrome Scale. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 53-89.	1.3	5
251	Cognition in schizophrenia: Past, present, and future. <i>Schizophrenia Research: Cognition</i> , 2014, 1, e1-e9.	1.3	181
252	A longitudinal examination of the moderating effects of symptoms on the relationship between functional competence and real world functional performance in Schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014, 1, 90-95.	1.3	36

#	ARTICLE	IF	CITATIONS
253	The Social Cognition Psychometric Evaluation Study: Results of the Expert Survey and RAND Panel. <i>Schizophrenia Bulletin</i> , 2014, 40, 813-823.	4.3	369
254	The Brief Assessment of Cognition In Affective Disorders (BAC-A):Performance of patients with bipolar depression and healthy controls. <i>Journal of Affective Disorders</i> , 2014, 166, 86-92.	4.1	43
255	Depression, deficits in functional capacity, and impaired glycemic control in urban African Americans with type 2 diabetes. <i>Journal of Psychiatric Research</i> , 2014, 52, 21-27.	3.1	19
256	Latent semantic variables are associated with formal thought disorder and adaptive behavior in older inpatients with schizophrenia. <i>Cortex</i> , 2014, 55, 88-96.	2.4	66
257	Development of the Spanish Brief-version of the University of California Performance Skills Assessment (Sp-UPSA-Brief) in patients with schizophrenia and bipolar disorder. <i>Revista De Psiquiatr�a Y Salud Mental (English Edition)</i> , 2014, 7, 113-120.	0.3	2
258	Cognition, functional capacity, and self-reported disability in women with posttraumatic stress disorder: Examining the convergence of performance-based measures and self-reports. <i>Journal of Psychiatric Research</i> , 2014, 57, 51-57.	3.1	35
259	Virtual reality functional capacity assessment in schizophrenia: Preliminary data regarding feasibility and correlations with cognitive and functional capacity performance. <i>Schizophrenia Research: Cognition</i> , 2014, 1, e21-e26.	1.3	44
260	The course and correlates of everyday functioning in schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2014, 1, e47-e52.	1.3	40
261	Neurocognition, functional capacity, and functional outcomes: The cost of inexperience. <i>Schizophrenia Research</i> , 2014, 152, 430-434.	2.0	47
262	Discovery of previously undetected intellectual disability by psychological assessment: A study of consecutively referred child and adolescent psychiatric inpatients. <i>Research in Developmental Disabilities</i> , 2014, 35, 1705-1710.	2.2	7
263	The course of vocational functioning in patients with schizophrenia: Re-examining social drift. <i>Schizophrenia Research: Cognition</i> , 2014, 1, e41-e46.	1.3	17
264	Development of a Virtual Reality Assessment of Everyday Living Skills. <i>Journal of Visualized Experiments</i> , 2014, , .	0.3	18
265	Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. <i>CNS Spectrums</i> , 2014, 19, 197-205.	1.2	35
266	Disability in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 15-20.	2.2	38
267	What Is the Evidence for Changes in Cognition and Functioning Over the Lifespan in Patients With Schizophrenia?. <i>Journal of Clinical Psychiatry</i> , 2014, 75, 34-38.	2.2	58
268	Functional outcomes, functional capacity, and cognitive impairment in schizotypal personality disorder. <i>Schizophrenia Research</i> , 2013, 144, 146-150.	2.0	46
269	Hospitalization and psychosis: Influences on the course of cognition and everyday functioning in people with schizophrenia. <i>Neurobiology of Disease</i> , 2013, 53, 18-25.	4.4	39
270	Subscale structure for the Positive and Negative Syndrome Scale (PANSS): A proposed solution focused on clinical validity. <i>Psychiatry Research</i> , 2013, 205, 137-142.	3.3	20



#	ARTICLE	IF	CITATIONS
271	Vocational functioning in schizotypal and paranoid personality disorders. <i>Psychiatry Research</i> , 2013, 210, 498-504.	3.3	24
272	Factor structure of the MATRICS Consensus Cognitive Battery (MCCB) in schizophrenia. <i>Schizophrenia Research</i> , 2013, 146, 244-248.	2.0	59
273	Validation of a European Spanish-version of the University of California performance Skills Assessment (Sp-UPSA) in patients with schizophrenia and bipolar disorder. <i>Schizophrenia Research</i> , 2013, 150, 421-426.	2.0	31
274	Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active-controlled study followed by a 6-month double-blind extension. <i>European Neuropsychopharmacology</i> , 2013, 23, 1373-1382.	0.7	69
275	Self-assessment of functional ability in schizophrenia: Milestone achievement and its relationship to accuracy of self-evaluation. <i>Psychiatry Research</i> , 2013, 207, 19-24.	3.3	51
276	Commentary on "Cognition in schizophrenia". <i>European Neuropsychopharmacology</i> , 2013, 23, 781-783.	0.7	1
277	Assessment of everyday functioning in schizophrenia: Implications for treatments aimed at negative symptoms. <i>Schizophrenia Research</i> , 2013, 150, 353-355.	2.0	53
278	The convergence between self-reports and observer ratings of financial skills and direct assessment of financial capabilities in patients with schizophrenia: More detail is not always better. <i>Schizophrenia Research</i> , 2013, 147, 86-90.	2.0	17
279	Prevalence and Precursors of the use of Restraint and Seclusion in a Private Psychiatric Hospital: Comparison of Child and Adolescent Patients. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2013, 40, 224-231.	2.1	27
280	Cognitive aspects of schizophrenia. <i>Wiley Interdisciplinary Reviews: Cognitive Science</i> , 2013, 4, 599-608.	2.8	4
281	Factor Structure of Neurocognition and Functional Capacity in Schizophrenia: A Multidimensional Examination of Temporal Stability. <i>Journal of the International Neuropsychological Society</i> , 2013, 19, 656-663.	1.8	25
282	Comparative impairments across schizophrenia and bipolar disorder. , 2013, , 50-68.		3
283	Cognition and work functioning in schizophrenia. , 2013, , 98-109.		6
284	Cognitive impairment and symptom dimensions in psychosis. , 2013, , 69-84.		2
285	Systematic Study of Structured Diagnostic Procedures in Outpatient Psychiatric Rehabilitation: A Three-year, Three-cohort Study of the Stability of Psychiatric Diagnoses. <i>Innovations in Clinical Neuroscience</i> , 2013, 10, 14-9.	0.1	15
286	Combined Cognitive Remediation and Functional Skills Training for Schizophrenia: Effects on Cognition, Functional Competence, and Real-World Behavior. <i>American Journal of Psychiatry</i> , 2012, 169, 710-718.	7.2	269
287	Cognitive impairment in schizophrenia: profile, course, and neurobiological determinants. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2012, 106, 433-445.	1.8	15
288	Impairment in Functional Capacity as an Endophenotype Candidate in Severe Mental Illness. <i>Schizophrenia Bulletin</i> , 2012, 38, 1318-1326.	4.3	27

#	ARTICLE	IF	CITATIONS
289	Diagnosis of schizophrenia: Consistency across information sources and stability of the condition. Schizophrenia Research, 2012, 140, 9-14.	2.0	20
290	Functional milestones and clinician ratings of everyday functioning in people with schizophrenia: Overlap between milestones and specificity of ratings. Journal of Psychiatric Research, 2012, 46, 1546-1552.	3.1	66
291	Age-Associated Differences in Cognitive Performance in Older Patients With Schizophrenia: A Comparison With Healthy Older Adults. American Journal of Geriatric Psychiatry, 2012, 20, 29-40.	1.2	66
292	Schizophrenia in Later Life. American Journal of Geriatric Psychiatry, 2012, 20, 1-4.	1.2	7
293	Cognitive Enhancement in Schizophrenia. Psychiatric Clinics of North America, 2012, 35, 683-698.	1.3	48
294	Predicting the severity of everyday functional disability in people with schizophrenia: cognitive deficits, functional capacity, symptoms, and health status. World Psychiatry, 2012, 11, 73-79.	10.4	233
295	The influence of demographic factors on functional capacity and everyday functional outcomes in schizophrenia. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 467-475.	1.3	30
296	Cognitive deficits, obesity and disability in schizophrenia. Translational Neuroscience, 2012, 3, .	1.4	8
297	Predictors of the accuracy of self assessment of everyday functioning in people with schizophrenia. Schizophrenia Research, 2012, 137, 190-195.	2.0	107
298	Functional impairment in people with schizophrenia: Focus on employability and eligibility for disability compensation. Schizophrenia Research, 2012, 140, 1-8.	2.0	134
299	Determinants of occupational and residential functioning in bipolar disorder. Journal of Affective Disorders, 2012, 136, 812-818.	4.1	24
300	Meta-analysis of the association between cognitive abilities and everyday functioning in bipolar disorder. Bipolar Disorders, 2012, 14, 217-226.	1.9	254
301	Functional Outcomes Assessment Scales. , 2012, , 33-38.		1
302	Clinical applications of neuropsychological assessment. Dialogues in Clinical Neuroscience, 2012, 14, 91-99.	3.7	157
303	Cognitive remediation in severe mental illness. Innovations in Clinical Neuroscience, 2012, 9, 27-30.	0.1	2
304	Technology, society, and mental illness: challenges and opportunities for assessment and treatment. Innovations in Clinical Neuroscience, 2012, 9, 47-50.	0.1	28
305	Development and Cross-Validation of the UPSA Short Form for the Performance-Based Functional Assessment of Patients With Mild Cognitive Impairment and Alzheimer Disease. American Journal of Geriatric Psychiatry, 2011, 19, 915-922.	1.2	50
306	Characteristics of the MATRICS Consensus Cognitive Battery in a 29-site antipsychotic schizophrenia clinical trial. Schizophrenia Research, 2011, 125, 161-168.	2.0	183

#	ARTICLE	IF	CITATIONS
307	Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. <i>Schizophrenia Research</i> , 2011, 127, 188-194.	2.0	86
308	Assessing everyday functioning in schizophrenia: Not all informants seem equally informative. <i>Schizophrenia Research</i> , 2011, 131, 250-255.	2.0	131
309	Sensitivity and specificity of the UCSD Performance-based Skills Assessment (UPSA-B) for identifying functional milestones in schizophrenia. <i>Schizophrenia Research</i> , 2011, 132, 165-170.	2.0	74
310	Performance-based assessment of functional skills in severe mental illness: Results of a large-scale study in China. <i>Journal of Psychiatric Research</i> , 2011, 45, 1089-1094.	3.1	48
311	Evaluation of Functionally Meaningful Measures for Clinical Trials of Cognition Enhancement in Schizophrenia. <i>American Journal of Psychiatry</i> , 2011, 168, 400-407.	7.2	147
312	Validating the Measurement of Real-World Functional Outcomes: Phase I Results of the VALERO Study. <i>American Journal of Psychiatry</i> , 2011, 168, 1195-1201.	7.2	168
313	Validating Measures of Real-World Outcome: The Results of the VALERO Expert Survey and RAND Panel. <i>Schizophrenia Bulletin</i> , 2011, 37, 334-343.	4.3	167
314	Neurocognitive Deficits, Negative Symptoms, and Insight in Schizophrenia. , 2011, , 33-74.		1
315	Assessment of everyday functioning in schizophrenia. <i>Innovations in Clinical Neuroscience</i> , 2011, 8, 21-4.	0.1	16
316	Mood symptoms, cognition, and everyday functioning: in major depression, bipolar disorder, and schizophrenia. <i>Innovations in Clinical Neuroscience</i> , 2011, 8, 14-8.	0.1	21
317	Relationship of the Brief UCSD Performance-based Skills Assessment (UPSA-B) to multiple indicators of functioning in people with schizophrenia and bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 45-55.	1.9	106
318	Cognition and disability in bipolar disorder: lessons from schizophrenia research. <i>Bipolar Disorders</i> , 2010, 12, 364-375.	1.9	130
319	Social competence and observer-rated social functioning in bipolar disorder. <i>Bipolar Disorders</i> , 2010, 12, 843-850.	1.9	43
320	Prediction of Real-World Functional Disability in Chronic Mental Disorders: A Comparison of Schizophrenia and Bipolar Disorder. <i>American Journal of Psychiatry</i> , 2010, 167, 1116-1124.	7.2	394
321	Evaluation of Dementia Rating Scales in Parkinson's Disease Dementia. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 142-148.	1.9	16
322	Circumstances Under Which Practice Does Not Make Perfect: A Review of the Practice Effect Literature in Schizophrenia and Its Relevance to Clinical Treatment Studies. <i>Neuropsychopharmacology</i> , 2010, 35, 1053-1062.	5.4	109
323	Pergolide Treatment of Cognitive Deficits Associated with Schizotypal Personality Disorder: Continued Evidence of the Importance of the Dopamine System in the Schizophrenia Spectrum. <i>Neuropsychopharmacology</i> , 2010, 35, 1356-1362.	5.4	51
324	The Course of Neuropsychological Performance and Functional Capacity in Older Patients with Schizophrenia: Influences of Previous History of Long-Term Institutional Stay. <i>Biological Psychiatry</i> , 2010, 67, 933-939.	1.3	75

#	ARTICLE	IF	CITATIONS
325	Cortical neuritic plaques and hippocampal neurofibrillary tangles are related to dementia severity in elderly schizophrenia patients. <i>Schizophrenia Research</i> , 2010, 116, 90-96.	2.0	30
326	Psychometric properties of performance-based measurements of functional capacity: Test-retest reliability, practice effects, and potential sensitivity to change. <i>Schizophrenia Research</i> , 2010, 119, 246-252.	2.0	67
327	Cognitive Functioning and Disability in Schizophrenia. <i>Current Directions in Psychological Science</i> , 2010, 19, 249-254.	5.3	23
328	Social cognition: the key factor predicting social outcome in people with schizophrenia?. <i>Psychiatry</i> , 2010, 7, 41-4.	0.3	39
329	Latest developments in the matrices process. <i>Psychiatry</i> , 2010, 7, 49-52.	0.3	7
330	Performance-Based Measurement of Functional Disability in Schizophrenia: A Cross-National Study in the United States and Sweden. <i>American Journal of Psychiatry</i> , 2009, 166, 821-827.	7.2	109
331	Systemic Hypotheses for Generalized Cognitive Deficits in Schizophrenia: A New Take on An Old Problem. <i>Schizophrenia Bulletin</i> , 2009, 35, 403-414.	4.3	121
332	Functional Recovery in Schizophrenia: Raising the Bar for Outcomes in People with Schizophrenia. <i>Schizophrenia Bulletin</i> , 2009, 35, 299-299.	4.3	16
333	Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. <i>Journal of Affective Disorders</i> , 2009, 119, 181-185.	4.1	145
334	Pharmacological Cognitive Enhancement in Schizophrenia. <i>Neuropsychology Review</i> , 2009, 19, 324-335.	4.9	86
335	Neurocognitive impairment in bipolar disorder patients: functional implications. <i>Bipolar Disorders</i> , 2009, 11, 113-125.	1.9	240
336	Letter to the Editor: reply to Magalhães et al.. <i>Bipolar Disorders</i> , 2009, 11, 901-901.	1.9	0
337	Abbreviated neuropsychological assessment in schizophrenia: Prediction of different aspects of outcome. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2009, 31, 462-471.	1.3	60
338	Toward a Terminology for Functional Recovery in Schizophrenia: Is Functional Remission a Viable Concept?. <i>Schizophrenia Bulletin</i> , 2009, 35, 300-306.	4.3	224
339	Development and psychometric performance of the schizophrenia objective functioning instrument: An interviewer administered measure of function. <i>Schizophrenia Research</i> , 2009, 107, 275-285.	2.0	40
340	Reduction of functional disability with atypical antipsychotic treatment: A randomized long term comparison of ziprasidone and haloperidol. <i>Schizophrenia Research</i> , 2009, 115, 24-29.	2.0	11
341	Determinants of everyday outcomes in schizophrenia: The influences of cognitive impairment, functional capacity, and symptoms. <i>Schizophrenia Research</i> , 2009, 115, 82-87.	2.0	197
342	Neuropsychological Function and Dysfunction in Schizophrenia and Psychotic Affective Disorders. <i>Schizophrenia Bulletin</i> , 2009, 35, 1022-1029.	4.3	427

#	ARTICLE	IF	CITATIONS
343	The Factor Structure of Clinical Symptoms in Depressed Inpatients With Unipolar or Bipolar Spectrum Disorders. <i>Journal of Nervous and Mental Disease</i> , 2009, 197, 161-165.	1.0	5
344	Is it possible to assess cognitive impairment other than with neuropsychological tests?. <i>Psychiatry</i> , 2009, 6, 23-5.	0.3	1
345	When does cognitive decline occur in the period prior to the first episode of schizophrenia?. <i>Psychiatry</i> , 2009, 6, 12-4.	0.3	9
346	Direct measurement of disability. <i>Psychiatry</i> , 2009, 6, 43-6.	0.3	3
347	The factor structure of clinical symptoms in mixed and manic episodes prior to and after antipsychotic treatment. <i>Bipolar Disorders</i> , 2008, 10, 900-906.	1.9	22
348	Usefulness of the UCSD performance-based skills assessment (UPSA) for predicting residential independence in patients with chronic schizophrenia. <i>Journal of Psychiatric Research</i> , 2008, 42, 320-327.	3.1	116
349	Age-associated differences in cognitive performance in older community dwelling schizophrenia patients: Differential sensitivity of clinical neuropsychological and experimental information processing tests. <i>Schizophrenia Research</i> , 2008, 106, 50-58.	2.0	42
350	A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment. <i>Schizophrenia Research</i> , 2008, 105, 138-143.	2.0	24
351	Introduction to the special section: The Eighth Biennial Mt. Sinai Conference on Cognition in Schizophrenia. <i>Schizophrenia Research</i> , 2008, 106, 1-2.	2.0	0
352	Communication abnormalities predict functional outcomes in chronic schizophrenia: Differential associations with social and adaptive functions. <i>Schizophrenia Research</i> , 2008, 103, 240-247.	2.0	97
353	Predicting Schizophrenia Patients'™ Real-World Behavior with Specific Neuropsychological and Functional Capacity Measures. <i>Biological Psychiatry</i> , 2008, 63, 505-511.	1.3	511
354	Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). <i>Schizophrenia Research</i> , 2008, 102, 108-115.	2.0	281
355	Six-year outcomes in first admission adolescent inpatients: Clinical and cognitive characteristics at admission as predictors. <i>Psychiatry Research</i> , 2008, 160, 47-54.	3.3	13
356	The Broad Importance of Cognitive Impairments in Aging-Related Disorders. <i>American Journal of Geriatric Psychiatry</i> , 2008, 16, 99-101.	1.2	3
357	Neuropsychological and symptom predictors of aggression on the psychiatric inpatient service. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2008, 30, 700-709.	1.3	51
358	Is Schizophrenia a Syndrome of Accelerated Aging?. <i>Schizophrenia Bulletin</i> , 2008, 34, 1024-1032.	4.3	258
359	Diffusion Tensor Imaging Findings in First-Episode and Chronic Schizophrenia Patients. <i>American Journal of Psychiatry</i> , 2008, 165, 1024-1032.	7.2	227
360	Cognition and the differential diagnosis of schizophrenia. <i>World Psychiatry</i> , 2008, 7, 30-32.	10.4	4

#	ARTICLE	IF	CITATIONS
361	Functional implications of neuropsychological normality and symptom remission in older outpatients diagnosed with schizophrenia: A cross-sectional study. <i>Journal of the International Neuropsychological Society</i> , 2008, 14, 479-488.	1.8	97
362	Context processing in schizotypal personality disorder: Evidence of specificity of impairment to the schizophrenia spectrum.. <i>Journal of Abnormal Psychology</i> , 2008, 117, 342-354.	1.9	49
363	A Pilot Study of Adjunctive Atomoxetine Treatment to Second-Generation Antipsychotics for Cognitive Impairment in Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 59-63.	1.4	49
364	The genetics of cognitive impairment in schizophrenia. <i>Psychiatry</i> , 2008, 5, 65-7.	0.3	1
365	CNTRICS: Bringing Clinical Treatment Trials Closer to the Brain. <i>Psychiatry</i> , 2008, 5, 57-9.	0.3	0
366	Performance-Based Measures of Functional Skills: Usefulness in Clinical Treatment Studies. <i>Schizophrenia Bulletin</i> , 2007, 33, 1138-1148.	4.3	218
367	Neurocognitive Effects of Antipsychotic Medications in Patients With Chronic Schizophrenia in the CATIE Trial. <i>Archives of General Psychiatry</i> , 2007, 64, 633.	12.3	928
368	Neuropsychological impairments in schizophrenia: Integration of performance-based and brain imaging findings.. <i>Psychological Bulletin</i> , 2007, 133, 833-858.	6.1	451
369	Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: Evidence for specificity of relationships?. <i>Schizophrenia Research</i> , 2007, 89, 330-338.	2.0	131
370	The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. <i>Schizophrenia Research</i> , 2007, 94, 99-106.	2.0	46
371	The Effects of Guanfacine on Context Processing Abnormalities in Schizotypal Personality Disorder. <i>Biological Psychiatry</i> , 2007, 61, 1157-1160.	1.3	62
372	Risperidone and Cognitive Function in Children With Disruptive Behavior Disorders. <i>Biological Psychiatry</i> , 2007, 62, 226-234.	1.3	26
373	Schizophrenia: Measurements of Psychopathology. <i>Psychiatric Clinics of North America</i> , 2007, 30, 339-363.	1.3	24
374	Self-assessment of functional status in schizophrenia. <i>Journal of Psychiatric Research</i> , 2007, 41, 1012-1018.	3.1	213
375	Managing Cognitive Deficits and Functioning in Patients With Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2007, 68, e21.	2.2	2
376	Cognitive Functioning and Acute Sedative Effects of Risperidone and Quetiapine in Patients With Stable Bipolar I Disorder. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1186-1194.	2.2	42
377	The Latest Developments in the MATRICS Initiative. <i>Psychiatry</i> , 2007, 4, 29-31.	0.3	2
378	Is cognitive impairment in schizophrenia multidimensional?: implications for assessment and treatment. <i>Psychiatry</i> , 2007, 4, 50-2.	0.3	0

#	ARTICLE	IF	CITATIONS
379	Cognitive Outcomes in the CATIE Schizophrenia Trial: Why do they seem different from previous results?. <i>Psychiatry</i> , 2007, 4, 20-3.	0.3	4
380	Will improving cognition change functional outcomes in schizophrenia?. <i>Psychiatry</i> , 2007, 4, 58-60.	0.3	1
381	Cognitive impairments in major depression and bipolar disorders. <i>Psychiatry</i> , 2007, 4, 12-4.	0.3	7
382	Administration and interpretation of the Trail Making Test. <i>Nature Protocols</i> , 2006, 1, 2277-2281.	12.0	942
383	Pharmacological Approaches to the Management of Cognitive Dysfunction in Schizophrenia. <i>Drugs</i> , 2006, 66, 1465-1473.	10.9	27
384	Premorbid intra-individual variability in intellectual performance and risk for schizophrenia: A population-based study. <i>Schizophrenia Research</i> , 2006, 85, 49-57.	2.0	47
385	Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: Retrospective comparison of first generation and second generation antipsychotics. <i>Schizophrenia Research</i> , 2006, 88, 127-134.	2.0	18
386	Dual-task information processing in schizotypal personality disorder: Evidence of impaired processing capacity.. <i>Neuropsychology</i> , 2006, 20, 453-460.	1.3	19
387	Convergence of Clinical Staff Ratings and Research Ratings to Assess Patients With Schizophrenia in Nursing Homes. <i>Psychiatric Services</i> , 2006, 57, 838-843.	2.0	8
388	Neuropsychological Normalization With Long-Term Atypical Antipsychotic Treatment: Results of a Six-Month Randomized, Double-Blind Comparison of Ziprasidone vs. Olanzapine. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2006, 18, 54-63.	1.8	36
389	The dimensions of clinical and cognitive change in schizophrenia: evidence for independence of improvements. <i>Psychopharmacology</i> , 2006, 187, 356-363.	3.1	55
390	Cognitive impairment in the schizophrenia spectrum: What is the evidence for similarity to schizophrenia?. <i>Current Psychosis &amp; Therapeutics Reports</i> , 2006, 4, 128-133.	0.1	0
391	The Relationship of the Brief Assessment of Cognition in Schizophrenia (BACS) to Functional Capacity and Real-world Functional Outcome. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006, 28, 260-269.	1.3	129
392	Validity and Stability of Performance-Based Estimates of Premorbid Educational Functioning in Older Patients with Schizophrenia. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006, 28, 178-192.	1.3	33
393	Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. <i>Neuropsychopharmacology</i> , 2006, 31, 2033-2046.	5.4	408
394	The Schizophrenia Cognition Rating Scale: An Interview-Based Assessment and Its Relationship to Cognition, Real-World Functioning, and Functional Capacity. <i>American Journal of Psychiatry</i> , 2006, 163, 426-432.	7.2	325
395	Improvement in Social Competence With Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning. <i>American Journal of Psychiatry</i> , 2006, 163, 1918-1925.	7.2	105
396	Negative Symptoms and Cognitive Deficits: What Is the Nature of Their Relationship?. <i>Schizophrenia Bulletin</i> , 2006, 32, 250-258.	4.3	379

#	ARTICLE	IF	CITATIONS
397	Determinants of Real-World Functional Performance in Schizophrenia Subjects: Correlations With Cognition, Functional Capacity, and Symptoms. <i>American Journal of Psychiatry</i> , 2006, 163, 418-425.	7.2	660
398	Premorbid Intellectual Functioning and Risk of Schizophrenia and Spectrum Disorders. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2006, 28, 193-207.	1.3	86
399	Cognition and Aging in Psychopathology: Focus on Schizophrenia and Depression. <i>Annual Review of Clinical Psychology</i> , 2006, 2, 389-409.	12.3	40
400	Cognitive deficits and functional outcome in schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2006, 2, 531-536.	2.2	420
401	Outcomes to Monitor When Treating Bipolar Disorder or Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2006, 67, e06.	2.2	4
402	Cognitive and Functional Effects of Atypical Antipsychotic Medications. <i>Journal of Clinical Psychiatry</i> , 2006, 67, e13.	2.2	41
403	Current Status of the MATRICS/ TURNS Initiative. <i>Psychiatry</i> , 2006, 3, 24-33.	0.3	1
404	Defining and achieving recovery from bipolar disorder. <i>Journal of Clinical Psychiatry</i> , 2006, 67 Suppl 9, 14-8; discussion 36-42.	2.2	6
405	From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone. <i>CNS Spectrums</i> , 2005, 10, 1-20.	1.2	36
406	The Validation of a Caregiver Assessment of Dementia. <i>Alzheimer Disease and Associated Disorders</i> , 2005, 19, 186-194.	1.3	15
407	Stability in schizophrenia symptoms over time: Findings from the Mount Sinai Pilgrim Psychiatric Center Longitudinal Study.. <i>Journal of Abnormal Psychology</i> , 2005, 114, 363-372.	1.9	40
408	Optimizing Treatment of Schizophrenia Enhancing Affective/Cognitive and Depressive Functioning. <i>CNS Spectrums</i> , 2005, 10, 1-1.	1.2	24
409	Cognitive Impairment in Schizophrenia. <i>CNS Spectrums</i> , 2005, 10, 7-9.	1.2	3
410	Neurocognition, Symptomatology, and Functional Skills in Older Alcohol-Abusing Schizophrenia Patients. <i>Schizophrenia Bulletin</i> , 2005, 31, 175-182.	4.3	56
411	The Longitudinal Course of Thought Disorder in Geriatric Patients With Chronic Schizophrenia. <i>American Journal of Psychiatry</i> , 2005, 162, 793-795.	7.2	42
412	Stability of Cognitive Performance in Older Patients With Schizophrenia: An 8-Week Test-Retest Study. <i>American Journal of Psychiatry</i> , 2005, 162, 110-117.	7.2	51
413	Treatment of Cognitive Impairment in Early Psychosis: A Comparison of Risperidone and Haloperidol in a Large Long-Term Trial. <i>American Journal of Psychiatry</i> , 2005, 162, 1888-1895.	7.2	148
414	Rates and Predictors of Adherence with Atypical Antipsychotic Medication: A Follow-Up Study of Adolescent Inpatients. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 901-912.	1.3	48



#	ARTICLE	IF	CITATIONS
415	Ziprasidone: efficacy, tolerability, and emerging data on wide-ranging effectiveness. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 337-346.	1.8	20
416	Depressed mood and its functional correlates in institutionalized schizophrenia patients. <i>Schizophrenia Research</i> , 2005, 77, 179-187.	2.0	20
417	Cognition in Schizophrenia: Impairments, Determinants, and Functional Importance. <i>Psychiatric Clinics of North America</i> , 2005, 28, 613-633.	1.3	207
418	Randomized, controlled, double-blind, multicenter comparison of the cognitive effects of ziprasidone versus olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. <i>Psychopharmacology</i> , 2004, 172, 324-332.	3.1	74
419	Stability and Functional Correlates of Memory-Based Classification in Older Schizophrenia Patients. <i>American Journal of Geriatric Psychiatry</i> , 2004, 12, 376-386.	1.2	18
420	The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients. <i>Schizophrenia Research</i> , 2004, 68, 11-19.	2.0	55
421	Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. <i>Schizophrenia Research</i> , 2004, 66, 101-113.	2.0	83
422	The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. <i>Schizophrenia Research</i> , 2004, 68, 283-297.	2.0	1,209
423	Disability Reduction in Elderly Patients with Schizophrenia. <i>Journal of Psychiatric Practice</i> , 2004, 10, 283-295.	0.7	5
424	Context-Processing Deficits in Schizotypal Personality Disorder.. <i>Journal of Abnormal Psychology</i> , 2004, 113, 556-568.	1.9	88
425	Cognitive Functioning in Schizophrenia. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 361-372.	2.2	191
426	Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. <i>Journal of Clinical Psychiatry</i> , 2004, 65, 361-72.	2.2	59
427	Cognitive functioning in schizophrenia. <i>Current Psychosis &amp; Therapeutics Reports</i> , 2003, 1, 22-27.	0.1	0
428	Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. <i>Psychopharmacology</i> , 2003, 169, 404-411.	3.1	132
429	Cognition in schizophrenia: from basic science to clinical treatment. <i>Psychopharmacology</i> , 2003, 169, 213-214.	3.1	20
430	Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 820-829.	2.7	67
431	Cross-national cognitive assessment in schizophrenia clinical trials: a feasibility study. <i>Schizophrenia Research</i> , 2003, 59, 243-251.	2.0	27
432	Convergence of Different Versions of the Continuous Performance Test: Clinical and Scientific Implications. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2003, 25, 283-292.	1.3	56

#	ARTICLE	IF	CITATIONS
433	Commentary: Chickens and Eggs; Carts and Horses: An Outsider's Perspective on the Study of the Early Stages and Potential Prevention of Psychosis and Schizophrenia. <i>Schizophrenia Bulletin</i> , 2003, 29, 845-849.	4.3	4
434	The Course of Functional Decline in Geriatric Patients With Schizophrenia: Cognitive-Functional and Clinical Symptoms as Determinants of Change. <i>American Journal of Geriatric Psychiatry</i> , 2003, 11, 610-619.	1.2	59
435	Ziprasidone and cognition: the evolving story. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 19, 33-9.	2.2	3
436	Cortical and Subcortical Cognitive Deficits in Schizophrenia: Convergence of Classifications Based on Language and Memory Skill Areas. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2002, 24, 55-66.	1.3	18
437	Correlates of Change in Functional Status of Institutionalized Geriatric Schizophrenic Patients: Focus on Medical Comorbidity. <i>American Journal of Psychiatry</i> , 2002, 159, 1388-1394.	7.2	69
438	Relationship Between Premorbid Functioning and Symptom Severity as Assessed at First Episode of Psychosis. <i>American Journal of Psychiatry</i> , 2002, 159, 2021-2026.	7.2	86
439	A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia. <i>Biological Psychiatry</i> , 2002, 51, 349-357.	1.3	170
440	The convergence of neuropsychological testing and clinical ratings of cognitive impairment in patients with schizophrenia. <i>Comprehensive Psychiatry</i> , 2001, 42, 306-313.	3.1	57
441	Diagnosis of manic episodes in adolescent inpatients: structured diagnostic procedures compared to clinical chart diagnoses. <i>Psychiatry Research</i> , 2001, 101, 47-54.	3.3	58
442	Aggression in Elderly Schizophrenia Patients. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 357-366.	1.8	21
443	Cognition in schizophrenia. <i>Current Psychiatry Reports</i> , 2001, 3, 423-428.	4.5	74
444	Cognitive impairment in elderly patients with schizophrenia: age related changes. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, S78-S85.	2.7	39
445	Guanfacine Treatment of Cognitive Impairment in Schizophrenia. <i>Neuropsychopharmacology</i> , 2001, 25, 402-409.	5.4	103
446	Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic Treatment. <i>American Journal of Psychiatry</i> , 2001, 158, 176-184.	7.2	581
447	Six-Year Follow-Up Study of Cognitive and Functional Status Across the Lifespan in Schizophrenia: A Comparison With Alzheimer's Disease and Normal Aging. <i>American Journal of Psychiatry</i> , 2001, 158, 1441-1448.	7.2	233
448	Relationship of Cognitive Functioning, Adaptive Life Skills, and Negative Symptom Severity in Poor-Outcome Geriatric Schizophrenia Patients. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2000, 12, 257-264.	1.8	32
449	Neuropsychological Differences Between First-Admission Schizophrenia and Psychotic Affective Disorders. <i>American Journal of Psychiatry</i> , 2000, 157, 1453-1460.	7.2	115
450	Practice-related improvement in information processing with novel antipsychotic treatment. <i>Schizophrenia Research</i> , 2000, 46, 139-148.	2.0	64

#	ARTICLE	IF	CITATIONS
451	Visuospatial working memory in schizotypal personality disorder patients. <i>Schizophrenia Research</i> , 2000, 41, 447-455.	2.0	75
452	Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas. <i>Biological Psychiatry</i> , 2000, 47, 962-968.	1.3	56
453	Cognitive decline in late-life schizophrenia: a longitudinal study of geriatric chronically hospitalized patients. <i>Biological Psychiatry</i> , 1999, 45, 32-40.	1.3	222
454	Convergence of cognitive and adaptive decline in late-life schizophrenia. <i>Schizophrenia Research</i> , 1999, 35, 77-84.	2.0	103
455	Memory performance of geriatric and nongeriatric chronic schizophrenic patients: A cross-sectional study. <i>Journal of the International Neuropsychological Society</i> , 1999, 5, 494-501.	1.8	20
456	Tardive dyskinesia in a chronically institutionalized population of elderly schizophrenic patients: prevalence and association with cognitive impairment. , 1998, 13, 473-479.		42
457	Age-related shift in brain region activity during successful memory performance. <i>Neurobiology of Aging</i> , 1998, 19, 437-445.	3.1	104
458	Symptoms, Cognitive Functioning, and Adaptive Skills in Geriatric Patients With Lifelong Schizophrenia: A Comparison Across Treatment Sites. <i>American Journal of Psychiatry</i> , 1998, 155, 1080-1086.	7.2	310
459	Learning and memory in adolescent psychiatric inpatients with major depression: A normative study of the California verbal learning test. <i>Archives of Clinical Neuropsychology</i> , 1997, 12, 575-584.	0.5	18
460	Association of MMPI Validity Scales and Therapist Ratings of Psychopathology in Adolescent Psychiatric Inpatients. <i>Assessment</i> , 1997, 4, 17-27.	3.1	7
461	Noncognitive Disturbances in Alzheimer's Disease: Frequency, Longitudinal Course, and Relationship to Cognitive Symptoms. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 1331-1338.	2.6	89
462	The association between adaptive and cognitive deficits in geriatric chronic schizophrenic patients. <i>Schizophrenia Research</i> , 1997, 27, 211-218.	2.0	52
463	Empirical Assessment of the Factorial Structure of Clinical Symptoms in Schizophrenia. <i>Psychopathology</i> , 1997, 30, 263-274.	1.5	334
464	CHARACTERISTICS OF ELDERLY PSYCHIATRIC PATIENTS RETAINED IN A STATE HOSPITAL DURING DOWNSIZING: A PROSPECTIVE STUDY WITH REPLICATION. , 1997, 12, 474-480.		39
465	Cognitive impairment in geriatric chronic schizophrenic patients: a cross-national study in New York and London. , 1997, 12, 1001-1007.		27
466	Cognitive impairment and negative symptoms in geriatric chronic schizophrenic patients: a follow-up study. <i>Schizophrenia Research</i> , 1996, 22, 223-231.	2.0	115
467	Information-processing markers of vulnerability to schizophrenia: performance of patients with schizotypal and nonschizotypal personality disorders. <i>Psychiatry Research</i> , 1996, 60, 49-56.	3.3	45
468	Symptom stability in geriatric chronic schizophrenic inpatients: A one-year follow-up study. <i>Biological Psychiatry</i> , 1996, 39, 92-99.	1.3	42

#	ARTICLE	IF	CITATIONS
469	Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: Effects of typical neuroleptics on the brief psychiatric rating scale. <i>Biological Psychiatry</i> , 1996, 40, 755-760.	1.3	36
470	Performance of chronic schizophrenic patients on cognitive neuropsychological measures sensitive to dementia. <i>International Journal of Geriatric Psychiatry</i> , 1996, 11, 621-627.	2.7	28
471	The Longitudinal Stability of Cognitive Impairment in Schizophrenia. <i>British Journal of Psychiatry</i> , 1995, 166, 630-633.	2.8	85
472	Empirical evaluation of the factorial structure of attention in adolescent psychiatric patients. <i>Journal of Clinical and Experimental Neuropsychology</i> , 1994, 16, 344-353.	1.3	20
473	A multimethod, multichannel assessment of affective flattening in schizophrenia. <i>Psychiatry Research</i> , 1994, 54, 211-222.	3.3	42
474	Performance of nonpsychotic relatives of schizophrenic patients on cognitive tests. <i>Psychiatry Research</i> , 1994, 53, 1-12.	3.3	133
475	Cognitive Deficits in Schizophrenia. <i>Psychiatric Clinics of North America</i> , 1993, 16, 295-312.	1.3	274
476	Psychometric vs. attentional correlates of early onset alcohol and substance abuse. <i>Journal of Abnormal Child Psychology</i> , 1992, 20, 151-162.	3.5	17
477	Medication may be required for the development of automatic information processing in schizophrenia. <i>Psychiatry Research</i> , 1990, 32, 281-288.	3.3	56
478	The affective lability scales: Development, reliability, and validity. <i>Journal of Clinical Psychology</i> , 1989, 45, 786-793.	1.9	278
479	Distractibility in children vulnerable to psychopathology.. <i>Journal of Abnormal Psychology</i> , 1981, 90, 298-304.	1.9	119
480	The importance of treating cognition in schizophrenia and other severe mental illnesses: background, strategies, and findings to date. , 0, , 177-191.		0
481	Cognitive functioning and awareness of illness in schizophrenia: a review and meta-analysis. , 0, , 142-160.		3
482	Cognition and functional status in adult and older patients with schizophrenia. , 0, , 110-125.		1
483	Performance-based measures of functioning in schizophrenia. , 0, , 247-265.		0